Neoadjuvant chemotherapy (NACT) is the standard-of-care treatment for 17%–40% of patients with operable early-stage breast cancer, particularly patients with HER2-positive (HER2+) and triple-negative breast cancer (TNBC; ref. 1). Here, ERBB2 is linked to triple-negative breast carcinoma.